# Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.

> **NCT03947762** · — · TERMINATED · sponsor: **Ipsen** · enrollment: 54 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Tumor

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03947762
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-03
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947762, "Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03947762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*